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The P2X7 receptor is not essential for development of imiquimod-induced 
psoriasis-like inflammation in mice 
Abstract 
Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia (acanthosis) 
and leukocyte infiltration of the skin. Current therapies are inadequate, highlighting the need for new 
therapeutic targets. The P2X7 receptor is implicated in the pathogenesis of psoriasis. This study 
investigated the role of P2X7 in imiquimod (IMQ)-induced psoriasis-like inflammation. Topically applied 
IMQ caused twofold greater ear swelling in BALB/c mice compared to C57BL/6 mice, which encode a 
partial loss-of-function missense mutation in the P2RX7 gene. However, there was no difference in 
histological skin pathology (acanthosis and leukocyte infiltration) between the two strains. IMQ treatment 
up-regulated P2X7 expression in skin from both mouse strains. Additionally, IMQ induced ATP release 
from cultured human keratinocytes, a process independent of cell death. Injection of the P2X7 antagonist 
Brilliant Blue G (BBG) but not A-804598 partly reduced ear swelling compared to vehicle-injected control 
mice. Neither antagonist altered skin pathology. Moreover, no difference in ear swelling or skin pathology 
was observed between C57BL/6 and P2X7 knock-out (KO) mice. Flow cytometric analysis of IMQ-treated 
skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including neutrophils, 
macrophages and T cells. In conclusion, this study demonstrates that P2X7 is not essential for 
development of IMQ-induced psoriasis-like inflammation but does not exclude a role for this receptor in 
psoriasis development in humans or other mouse models of this disease. 
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Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia 
(acanthosis) and leukocyte infiltration of the skin. Current therapies are inadequate, 
highlighting the need for new therapeutic targets. The P2X7 receptor is implicated in the 
pathogenesis of psoriasis. This study investigated the role of P2X7 in imiquimod (IMQ)-
induced psoriasis-like inflammation. Topically-applied IMQ caused two-fold greater ear 
swelling in BALB/c mice compared to C57BL/6 mice, which encode a partial loss-of-
function missense mutation in the P2RX7 gene. However, there was no difference in 
histological skin pathology (acanthosis and leukocyte infiltration) between the two strains. 
IMQ treatment up-regulated P2X7 expression in skin from both mouse strains. Additionally, 
IMQ induced ATP release from cultured human keratinocytes, a process independent of cell 
death. Injection of the P2X7 antagonist Brilliant Blue G (BBG) but not A-804598 partly 
reduced ear swelling compared to vehicle-injected control mice. Neither antagonist altered 
skin pathology. Moreover, no difference in ear swelling or skin pathology was observed 
between C57BL/6 and P2X7 knock-out (KO) mice. Flow cytometric analysis of IMQ-treated 
skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including 
neutrophils, macrophages and T cells. In conclusion, this study demonstrates that P2X7 is not 
essential for development of IMQ-induced psoriasis-like inflammation, but does not exclude 












Psoriasis affects 1-3% of the general population of Western countries, reducing quality of life 
and posing a significant economic burden [1]. In the USA alone, psoriasis is estimated to cost 
$112 billion per year [2]. Inflammation and hyper-proliferation of keratinocytes in psoriasis 
results in epidermal hyperplasia (acanthosis) and plaque- or pustular-like skin lesions [3]. 
This characteristic inflammation is driven by infiltrating leukocytes, including neutrophils, 
macrophages and T cells [4]. These leukocytes exert their effects by release of pro-
inflammatory cytokines such as interferon gamma (IFN-γ) [3,4], which promotes the hyper-
proliferation of keratinocytes, with the resulting cell damage exacerbating inflammation and 
leading to plaque formation [4].  
The imiquimod (IMQ)-induced psoriasis-like inflammation mouse model is a valuable model 
for studying psoriasis pathogenesis. This model involves application of AldaraTM cream, 
containing IMQ, which causes epidermal hyperplasia and immune infiltration similar to 
psoriasis in humans [5]. IMQ treatment results in scaling and thickening of skin as well as 
infiltration of immune cells 48-72 hours after first application [5]. This model has been well 
characterised [6] and used in some 200 different studies to date [7].  
The ATP-gated P2X7 receptor channel has been implicated in a number of skin diseases 
including psoriasis [8]. P2X7 is present on keratinocytes [9] and immune cells important in 
psoriasis including neutrophils [10], macrophages [11] and T cells [12], where its activation 
can drive cytokine release and potentially promote inflammation [8]. Notably, IFN-γ can up-
regulate the expression of P2X7 in primary keratinocytes [13] and P2X7 expression is 
increased in human psoriatic lesions [13,14]. A functional role for P2X7 in psoriasis has also 
been suggested. Injection of the P2X7 agonist 3’-O-(4-benzoyl)benzoyl ATP into normal 
human skin explants induces increased expression of cytokines and other molecules 





factor alpha (TNF-α) [14]. Importantly, these responses could be prevented through 
pharmacological blockade of P2X7 [14]. P2X7 activation of skin migrating dendritic cells 
also promoted Th17 responses [14], a T cell subtype known to contribute to psoriasis 
pathogenesis [15]. 
This study investigated the role of P2X7 in the pathogenesis of psoriasis using a murine 
model of IMQ-induced psoriasis-like inflammation. Results indicate that P2X7 is up-
regulated in psoriatic skin in both BALB/c and C57BL/6 mice, which encode the wild-type 
(P451) or partial loss-of function (451L) allele, respectively [16]. IMQ also induced ATP 
release from human keratinocytes. However, pharmacological blockade or genetic deletion of 










Human HaCaT keratinocytes and murine J774 macrophages were obtained and cultured as 
described [17,18]. Cell lines were checked for Mycoplasma spp. infections every two months, 
using a MycoAlertTM Mycoplasma detection kit (Lonza, Basal, Switzerland) as per the 
manufacturer’s instructions. Cells were routinely negative for Mycoplasma spp.  
Mice 
Female and male mice (aged 6-10 weeks) were used in experiments conducted under protocol 
AE14/10, which was approved by the University of Wollongong Animal Ethics Committee 
(Wollongong, Australia). BALB/c and C57BL/6 mice were obtained from Australian 
BioResources (Moss Vale, Australia). P2X7 knock-out (KO) mice [19] backcrossed onto a 
C57BL/6 background [20], were maintained at the University of Wollongong and genotyped 
as described [19]. All mice were housed in open top cages and provided with food and water, 
ad libitum. All mice were housed in a temperature-controlled environment with a 12 h 
light/12 h dark cycle. 
Murine model of IMQ-induced psoriasis-like inflammation 
A total of 25 mg of AldaraTM cream (1.25 mg IMQ) (iNova Pharmaceuticals, Thornleigh, 
Australia) was applied to both sides of one ear of each mouse and the contralateral ear 
remained untreated (control) (days 0-5) as described [21]. Prior to treatment mice were 
weighed and ear measurements were recorded using Interapid (Rolle, Switzerland) spring-
loaded calipers (days 0-6). In some experiments, Brilliant Blue G (BBG) or A-804598 (both 





respective diluent controls (saline or dimethyl sulfoxide (DMSO), respectively), were 
injected every second day (as indicated). Mice were sacrificed on day 6 and ears collected. 
Histological analysis 
Ears from euthanised mice were incubated overnight in neutral buffered (10%) formalin 
(Sigma-Aldrich). Fixed tissues were removed, embedded in paraffin, sectioned (5 µm) and 
stained with haematoxylin and eosin (POCD, Artarmon, Australia). Histology was observed 
using a Leica (Wetzlar, Germany) DM500 inverted light microscope, with images captured 
and processed using Leica application suite software version 4.7. Acanthosis (epidermal 
thickness) was measured using ImageJ software version 1.48 (National Institutes of Health, 
Bethesda, MD, USA). 
Isolation of RNA and cDNA synthesis 
Ears from euthanised mice were stored in RNAlater (Sigma-Aldrich) at -20°C until required. 
RNA was isolated using the ISOLATE II RNA Mini Kit (Bioline, London, UK) as per the 
manufacturer’s instructions. Briefly, tissue in lysis buffer containing 1% (v/v) β-
mercaptoethanol (Sigma-Aldrich) was homogenised (two 20 second cycles at 5500 rpm) in a 
Bertin Technologies (Montigny-le-Bretonneux, France) Precellys 24 tissue homogeniser. 
Isolated RNA was immediately converted to cDNA using the qScript cDNA Synthesis Kit 
(Quanta Biosciences, Gaithersburg, MD, USA) as per the manufacturer’s instructions. cDNA 
was checked by PCR amplification of the house keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (Invitrogen, Carlsbad, CA, USA) for 35 cycles at 95°C for 1 min, 55°C for 1 
min and 72°C for 1 min and a holding temperature of 4°C. Purity and size of amplicons were 





Quantitative real-time polymerase chain reaction 
qPCR reactions were performed using TaqMan Universal Master Mix II (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions with 
primers for FAM-labelled GAPDH (Mm99999915_g1) and VIC-labelled P2RX7 
(Mm01199503_m1) (Thermo Fisher Scientific). qPCR cycles consisted of an initial step of 
50°C for 2 min, followed by 50°C for 10 min, and 40 cycles at 95°C for 15 s, and 60°C for 1 
min. qPCR reactions were conducted in triplicate on a Roche Diagnostics (Indianapolis, IN, 
USA) LightCycler 480 and analysis was conducted using LightCycler480 software version 
1.5.1.  
ATP release assay 
ATP release assays were performed as described [22]. Briefly, HaCaT keratinocytes were 
plated in 12-well plates (Greiner Bio-One, Frickenhausen, Germany) at a concentration of 2 x 
105 cells/well in RPMI 1640 medium containing 2 mM L-glutamine, 1% non-essential amino 
acids (all Thermo Fisher Scientific), and 10% (v/v) heat-inactivated foetal bovine serum 
(Bovogen Biologicals, Keller East, Australia), and incubated for 24 h at 37°C/5% CO2. Cells 
were washed thrice with PBS (Thermo Fisher Scientific), and incubated in 1 mL PBS 
containing DMSO or 1 µg/mL IMQ (Sigma-Aldrich) in DMSO for 30 min at 37°C/5% CO2. 
The final concentration of DMSO in both groups was 0.1%. Cells were then centrifuged 
through 10% bovine serum albumin (4,000 x g for 3 min) and cell free supernatants were 
stored in duplicate at -20°C until required. ATP concentrations in supernatants were assessed 
using a Bioluminescence ATP Assay Kit (Sigma-Aldrich) as described [23]. The amount of 
lactate dehydrogenase (LDH) in supernatants was determined using a Cytotoxicity Detection 
Kit (LDH) (Roche Diagnostics) as per the manufacturer’s instructions using a Molecular 





ATP-induced ethidium+ uptake assay 
P2X7 pore formation was quantified by measuring ATP-induced ethidium+ uptake as 
described [24]. Briefly, J774 cells in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM 
glucose and 10 mM HEPES, pH 7.5) were pre-incubated in the absence or presence of BBG 
or A-804598 (as indicated) for 15 min at 37°C. Cells were then incubated with 25 µM 
ethidium bromide (Sigma-Aldrich) in the absence or presence of 1 mM ATP (Sigma-Aldrich) 
for 10 min. Incubations were stopped by addition of ice-cold NaCl medium containing 20 
mM MgCl2 (MgCl2 medium) and cells were washed with NaCl medium (300 x g for 3 min). 
Data was collected using a BD Biosciences (San Jose, CA, USA) LSRFortessa X-20 flow 
cytometer (using band-pass filter 530/30 for ethidium+) and FACSDiva software version 8.0. 
Mean fluorescence intensity (MFI) of ethidium+ uptake was analysed using FlowJo software 
version 8.7.1. (TreeStar Inc., Ashland, OH, USA). 
Immunophenotyping 
CD16/32 Fc Block (clone 2-4G2), Brilliant Violet (BV)450-conjugated rat anti-mouse Ly-6G 
(clone 1A8), peridinin chlorophyll protein (PerCP)-conjugated rat anti-mouse CD4 (clone 
RM4.5), allophycocyanin (APC)-conjugated rat anti-mouse CD45 (clone 30-F11) and R-
phycoerythrin (PE)-Cy7 conjugated hamster anti-mouse CD3e (clone 145-2C11) were from 
BD Biosciences. PE-conjugated rat anti-mouse CD11b (clone M1/70) was from BioLegend 
(San Diego, CA, USA). 
Enzymatic digestion of ears was performed as described [25]. Briefly, dorsal and ventral 
sides of ears were separated and incubated in 20 mM EDTA (Sigma-Aldrich) in Tris-buffered 
saline (pH 7.3) for 2 hours at 37°C. Epidermal and dermal layers were mechanically 
separated, cut into smaller fragments using a scalpel and homogenised in RPMI 1640 





and 5% heat-inactivated foetal bovine serum at room temperature for 90 min with agitation. 
Enzymatic digestion was stopped by addition of 100 mM EDTA and suspensions filtered 
through 70 µm cell strainers (Falcon, Franklin, NJ, USA). Cells were centrifuged (300 x g for 
5 min), resuspended in PBS and counted manually using a Boeco (Hamburg, Germany) 
Neubauer Improved Bright Line haemacytometer. Cells were incubated with CD16/32 Fc 
Block for 10 min and then with fluorochrome-conjugated monoclonal antibodies in the dark 
for 10 min. Cells were washed twice with PBS (300 x g for 3 min), resuspended in PBS and 
data was collected using a LSRFortessa X-20 flow cytometer (using band pass filters 450/50 
for BV421, 695/40-A for PerCP, 575/25-A for PE, 780/60 for PE-Cy7 and 670/30 for APC) 
and FACSDiva software. The relative percentage of cells was analysed using FlowJo 
software. 
Statistical Analysis 
Data is given as mean ± standard error of the mean (SEM). Statistical differences were 
calculated using Student’s t test for single comparisons or one-way analysis of variance 
(ANOVA) with Tukeys post-hoc test for multiple comparisons. Weight and ear 
measurements were analysed using a repeated measures two-way ANOVA. All statistical 
analyses and graphs were generated using Prism 5 for Windows software (GraphPad 







IMQ treatment induces greater ear swelling in BALB/c mice compared to C57BL/6 
mice 
To investigate the role of P2X7 in psoriasis, IMQ-induced psoriasis-like inflammation was 
first compared over 6 days in BALB/c and C57BL/6 mice. C57BL/6 mice encode a loss-of-
function mutation (P451L) in the P2RX7 gene, while BALB/c mice are wild-type at this 
allele [16]. IMQ induced ear swelling in ears relative to control (contralateral untreated) ears 
from day 3 in both strains (Fig. 1a). However, IMQ-induced ear swelling was greater in 
BALB/c mice compared to C57BL/6 mice over 6 days (P < 0.0001) (Fig. 1a). Histological 
analysis of IMQ-treated ears from BALB/c and C57BL/6 mice demonstrated acanthosis 
(epidermal thickening) and leukocyte infiltration compared to control ears; however, there 
was no difference between strains (Fig. 1b). Image analysis of histological sections revealed 
that epidermal thickness was significantly greater in IMQ-treated ears compared to control 
ears from both BALB/c mice (P < 0.0001) and C57BL/6 mice (P < 0.0001). However, IMQ-
induced epidermal thickening did not significantly differ between the two strains (Fig. 1c).  
 
P2X7 mRNA is up-regulated in IMQ-induced psoriatic lesions and IMQ induces ATP 
release from keratinocytes 
Next, P2X7 mRNA expression in IMQ-treated and control ears was analysed by qPCR. P2X7 
was significantly up-regulated almost three-fold and two-fold in IMQ-treated ears compared 
to control ears from BALB/c mice (P = 0.0002) and C57BL/6 mice (P = 0.0343), 
respectively (Fig. 2a). To further determine a potential role for P2X7 activation in IMQ-





1 µg/mL IMQ or DMSO (vehicle control) for 30 min and the amount of ATP released 
measured using a bioluminescence assay. IMQ induced significantly greater amounts of ATP 
release compared to DMSO (P = 0.0425) (Fig. 2b). To examine if this ATP release was due 
to cytotoxicity by IMQ, the relative amount of LDH in the above supernatants was 
determined using a spectrophotometric assay. Although the absorbance in the IMQ cells was 
reduced the absorbance values were not significantly different between IMQ and control 
groups (Fig. 2c). 
 
BBG does not prevent IMQ-induced psoriasis-like inflammation 
To investigate the role of P2X7 in IMQ-induced psoriasis-like inflammation, the P2X7 
antagonist BBG [26] was used in this model. First, to confirm that BBG can impair murine 
P2X7 activation, J774 macrophages, which express functional P2X7 [27], were pre-incubated 
in the absence or presence of 10 µM BBG and ATP-induced cation dye uptake was measured 
by flow cytometry. BBG significantly reduced ATP-induced ethidium+ uptake by 87% (P < 
0.0001) (Fig. 3a). To determine if BBG could prevent the development of IMQ-induced 
psoriasis-like inflammation BALB/c mice were treated with IMQ as above and injected with 
BBG or saline (vehicle control) every second day (days 0, 2 and 4). IMQ induced ear 
swelling in mice from day 3 regardless of treatment. However, IMQ-induced ear swelling 
was partially reduced (by 21%) in BBG-injected mice compared to saline-injected mice over 
6 days (P = 0.0068) (Fig. 3b). Histological analysis of IMQ-treated ears from BBG- and 
saline-injected mice demonstrated epidermal thickening and leukocyte infiltration compared 
to control ears; but there were no differences between BBG and saline treatments (Fig. 3c). 
Image analysis of histological sections revealed that epidermal thickness was greater in IMQ-





injected mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was similar 
between BBG and saline treatments (Fig. 3d).  
A-804598 does not prevent IMQ-induced psoriasis-like inflammation 
To further examine the potential effects of P2X7 blockade on psoriasis-like inflammation, the 
P2X7 antagonist A-804598 [28] was used. Similar to BBG, A-804598 near-completely 
abrogated ATP-induced ethidium+ uptake in J774 macrophages (P < 0.0001) (Fig. 4a). 
BALB/c mice were treated with IMQ as above and injected with A-804598 or DMSO 
(vehicle control) every second day (days 0 and 2). IMQ induced ear swelling in mice from 
day 3 regardless of treatment. A-804598- and DMSO-injected mice demonstrated similar ear 
swelling (Fig. 4b). Histological analysis of IMQ-treated ears from A-804598-injected and 
DMSO-injected mice demonstrated epidermal thickening and leukocyte infiltration compared 
to control ears with no difference between A-804598 and control treatments (Fig. 4c). Image 
analysis of histological sections revealed that epidermal thickness was greater in IMQ-treated 
ears compared to control ears from A-804598-injected mice (P < 0.0001) and DMSO-
injected mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was also 
similar between A-804598 and control treatments (Fig. 4d). 	
Genetic deletion of P2X7 does not prevent IMQ-induced psoriasis-like inflammation  
Finally, to determine if genetic deficiency of P2X7 could alter IMQ-induced psoriasis-like 
inflammation, C57BL/6 and P2X7 KO mice were treated with IMQ as above. Both C57BL/6 
and P2X7 KO mice demonstrated ear swelling in IMQ-treated ears from day 3, but this was 
not significantly different between the two strains over 6 days (Fig. 5a). Histological analysis 
of IMQ-treated ears from C57BL/6 and P2X7 KO mice demonstrated epidermal thickening 





5b). Image analysis of histology revealed that epidermal thickness was significantly greater in 
IMQ-treated ears compared to control ears from C57BL/6 mice (P < 0.0001) and P2X7 KO 
mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was also similar 
between C57BL/6 and P2X7 KO mice (Fig. 5c).	
IMQ-induced leukocyte infiltration is similar in C57BL/6 and P2X7 KO mice 
The data above indicates that P2X7 deficiency does not prevent IMQ-induced psoriasis-like 
inflammation in mice. However, the possibility remained that P2X7 deficiency may have 
altered the number of leukocyte subsets infiltrating the skin in this disease model. Therefore, 
whole ear cell suspensions of IMQ-treated and control ears from C57BL/6 and P2X7 KO 
mice were examined by flow cytometry. IMQ induced a significant increase in total skin 
leukocytes in both C57BL/6 (P = 0.0002) and P2X7 KO (P = 0.0029) mice, but there was no 
significant difference between strains (Figure 6a). Subset analysis also revealed IMQ induced 
a significant increase in neutrophils and macrophages in both C57BL/6 (P = 0.0027 and P < 
0.0001, respectively) and P2X7 KO (P = 0.0020 and P = 0.0046, respectively) mice, but there 
was no significant difference between strains (Figure 6b-c). IMQ induced a significant 
increase in T cells in C57BL/6 (P = 0.0006) but not P2X7 KO mice; yet there was no 








This study demonstrated that P2X7 is not essential for the development of IMQ-induced 
psoriasis-like inflammation in mice. With the exception of a partial effect on ear swelling by 
BBG, pharmacological blockade or genetic deletion of P2X7 did not impact development of 
IMQ-induced psoriasis-like inflammation. The general lack of effect of either P2X7 
antagonist was not due to the preparations of BBG or A-804598, as both compounds blocked 
ATP-induced dye uptake into murine macrophages in this study. Moreover, both compounds 
were used in vivo at concentrations known to inhibit murine P2X7 [29]. In regards to IMQ-
induced ear swelling, BBG may be blocking alternate molecules, such as P2X1 [30], P2X5 
[31], the ATP channel pannexin-1 [32] or a voltage-gated sodium channel [33]. 
Genetic deficiency of P2X7 did not impact leukocyte infiltration in IMQ-induced psoriasis-
like inflammation. In contrast, a previous study reported that P2X7 KO mice had reduced 
neutrophil infiltration into skin in a croton oil model of irritant contact dermatitis [34]. 
However, in line with our current study, ear swelling was similar between wild-type and 
P2X7 KO mice in croton oil-induced irritant contact dermatitis [34,35]. Conversely, P2X7 
KO mice are protected from allergic contact dermatitis, which was also assessed by ear 
swelling measurements [35]. This previous study demonstrated that P2X7-mediated IL-1β 
release, which requires NLRP3 inflammasome activation [36], was essential for allergic 
contact dermatitis [35]. In contrast, activation of the NLRP3 inflammasome is not required 
for IMQ-induced psoriasis-like inflammation [37]. Thus, this provides a possible explanation 
as to why P2X7 is not essential in this model of psoriasis. Collectively, this indicates P2X7 
plays differing roles in various inflammatory skin disorders, but given previous findings 
[13,14] further investigation of P2X7 in human psoriasis and other mouse models of this 
disease is warranted. Moreover, it should be noted that C-terminal truncated P2X7 variants 





in the current study. Although P2X7-induced pore formation is absent in splenic T and B 
cells [39], epidermal Langerhans cells and keratinocytes [20] from these P2X7 KO mice, a 
role for these escape P2X7 variants in IMQ-induced psoriasis-like inflammation in P2X7 KO 
mice cannot be excluded. P2X7 KO strains in which escape variants have not been reported, 
such as those from Lexicon Pharmaceuticals [40] or conditional humanised P2X7 KO mice 
[41], provide alternatives to assess the potential role of P2X7 in psoriasis. 
Ear swelling, but not histological acanthosis or inflammation, differed between BALB/c and 
C57BL/6 mice. Thus, this difference in ear swelling most likely reflects differences in 
oedema. Coincidentally, this difference in ear swelling corresponds to P2RX7 genotype 
(P451L mutation), but P2X7 deficiency in mice on a C57BL/6 background does not alter ear 
swelling compared to wild-type C57BL/6 mice. This suggests that the difference between 
BALB/c and C57BL/6 mice is not due to reduced P2X7 activity as a result of the P451L 
mutation in C57BL/6 mice. In this regard, whilst some have reported that the P451L mutation 
results in a loss of P2X7 activity [16,42], others have observed no differences in the activity 
or pharmacological profiles between recombinant BALB/c and C57BL/6 P2X7 [43]. 
Moreover, it remains to be established if P2X7 variants differ between BALB/c and C57BL/6 
mice, and if P2X7 activity differs between these two mouse strains in vivo. BALB/c and 
C57BL/6 mice have a diverse lineage and display phenotypic and genetic differences [44,45]. 
Thus, differences in IMQ-induced ear swelling between these strains could be due to any 
number of genotypic or phenotypic differences. Notably, IL-22 expression is increased in 
IMQ-induced psoriasis-like inflammation in BALB/c, but not C57BL/6, mice [5]. 
Conversely, IL-6 is detected in C57BL/6 mice, but not BALB/c mice [5]. Thus, a role for 
these cytokines in oedema during psoriasis warrants further investigation. 
Analysis by qPCR revealed P2X7 mRNA expression was up-regulated in IMQ-treated skin in 





increased in these mice, P2X7 protein is increased in lesional skin from psoriasis patients 
[13,14]. Notably, P2X7 is up-regulated on human keratinocytes by IFN-γ [13], a cytokine 
implicated in psoriasis pathogenesis [46] including IMQ-induced psoriasis-like inflammation 
[5]. Therefore, P2X7 may be up-regulated on keratinocytes due to IFN-γ present in IMQ-
treated skin. Alternatively, since P2X7 is also found on various skin immune cells [8], 
increased P2X7 expression in IMQ-treated ears may simply reflect increased numbers of 
infiltrating leukocytes in IMQ-induced skin as observed in the current study.  
Finally, this study demonstrated that HaCaT keratinocytes can constitutively release ATP, as 
previously observed [47], and that this release could be increased by IMQ. The IMQ-induced 
ATP release was not due to cytotoxicity, as IMQ did not significantly alter LDH release. 
Although genetic deletion or pharmacological blockade of P2X7 did not impact IMQ-induced 
psoriasis-like inflammation in this study, extracellular ATP may be involved in the 
development of this disease through activation of purinergic receptors other than P2X7. In 
particular, P2Y1, P2Y2 and P2Y6 have been implicated in psoriasis or other inflammatory 
skin conditions [48].  
In conclusion, pharmacological blockade and genetic deletion of P2X7 could not prevent 
IMQ-induced psoriasis-like inflammation. However, given the potential roles of P2X7 in 
human psoriasis [13,14] and other skin diseases [8], a role for this receptor in human 
psoriasis or other mouse models of this disease cannot be excluded. 
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Figure 1 IMQ treatment induces greater ear swelling in BALB/c mice compared to 
C57BL/6 mice.  
(a-b) AldaraTM cream (containing 5% IMQ) was applied to one ear of BALB/c and C57BL/6 
mice from day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was 
measured over 6 days. Data represents group means ± SEM (n = 14 per strain). *** P < 
0.0001 compared to C57BL/6. (b) Ears from mice at end-point were stained with 
haematoxylin and eosin, and viewed by microscopy. Each image is representative of 14 mice 
per group. Bars represent 200 µm. (c) Epidermal thickness was measured on histological 
images using ImageJ. Data represents group means ± SEM (n = 14 mice per group); symbols 
represent individual ears; *** P < 0.0001 compared to corresponding control. 
Figure 2 P2X7 is up-regulated in IMQ-treated skin and IMQ can induce ATP release 
from keratinocytes. 
(a) P2X7 expression in untreated (control) and IMQ-treated ears from BALB/c and C57BL/6 
mice at end-point (Fig. 1) was assessed by qPCR. Data represents group means ± SEM (n = 5 
mice per strain); symbols represent individual ears; * P < 0.05, *** P < 0.0001 compared to 
corresponding control. (b and c) Human HaCaT keratinocytes were incubated in DMSO or 1 
µg/mL IMQ for 30 min and (b) ATP release assessed using a bioluminescence assay, and (c) 
LDH release was assessed using a spectrophotometric assay. Data represents group means ± 





Figure 3 BBG does not prevent IMQ-induced psoriasis-like inflammation.  
(a) Murine J774 macrophages were incubated for 15 min at 37°C in the absence or presence 
of 10 µM BBG, and then with 25 µM ethidium bromide in the absence or presence of 1 mM 
ATP for 10 min at 37°C. Assays were stopped by addition of MgCl2 medium, and ethidium+ 
uptake was then assessed by flow cytometry. Data represents group means ± SEM (n = 3); * 
P < 0.05, *** P < 0.0001 compared to corresponding basal. (b-d) AldaraTM cream 
(containing 5% IMQ) was applied to one ear of BALB/c mice from day 0 to 5. Contralateral 
ears were left untreated (control). Mice were injected i.p. with BBG or saline (control) on 
days 0, 2, and 4. (b) Ear swelling was measured over 6 days. Data represents group means ± 
SEM (n = 5 mice per treatment); ** P < 0.005 compared to BBG. (c) Ears from mice at end-
point were stained with haematoxylin and eosin, and viewed by microscopy. Each image is 
representative of 5 mice per treatment. Bars represent 200 µm. (d) Epidermal thickness was 
measured on histological images using ImageJ. Data represents group means ± SEM (n = 5 
mice per treatment); symbols represent individual ears; *** P < 0.0001 compared to 
corresponding control. 
Figure 4 A-804598 does not prevent IMQ-induced psoriasis-like inflammation. 
(a) Murine J774 macrophages were incubated for 15 min at 37°C in the absence or presence 
of 1 µM A-804598, and then with 25 µM ethidium bromide in the absence or presence of 1 
mM ATP for 10 min at 37°C. Assays were stopped by addition of MgCl2 medium, and 
ethidium+ uptake was then assessed by flow cytometry. Data represents group means ± SEM 
(n = 3); *** P < 0.0001 compared to corresponding basal. (b-d) AldaraTM cream (containing 
5% IMQ) was applied to one ear of BALB/c mice from day 0 to 5. Contralateral ears were 
left untreated (control). Mice were injected i.p. with A-804598 or DMSO (control) on days 0 





5 mice per treatment). (c) Ears from mice at end-point were stained with haematoxylin and 
eosin, and viewed by microscopy. Each image is representative of 5 mice per treatment. Bars 
represent 200 µm. (d) Epidermal thickness was measured on histological images using 
ImageJ. Data represents group means ± SEM (n = 5 mice per treatment); symbols represent 
individual ears; *** P < 0.0001 compared to corresponding control. 
Figure 5 Genetic deletion of P2X7 does not prevent IMQ-induced psoriasis-like 
inflammation. 
(a-c) AldaraTM cream (containing 5% IMQ) was applied to ears of C57BL/6 and P2X7 KO 
mice from day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was 
measured over 6 days. Data represents group means ± SEM (n = 10 mice per strain).  (b) Ears 
from mice at end-point were stained with haematoxylin and eosin, and viewed by 
microscopy. Each image is representative of 10 mice per group. Bars represent 200 µm. (c) 
Epidermal thickness was measured on histological images using ImageJ. Data represents 
group means ± SEM (n = 10 mice per strain); symbols represent individual ears; *** P < 
0.0001 compared to corresponding control. 
Figure 6 IMQ-induced leukocyte infiltration is similar in C57BL/6 and P2X7 KO mice.  
(a-d) Single whole ear cell suspensions of ears from untreated (control) and IMQ-treated 
C57BL/6 and P2X7 KO mice at end-point (Fig. 5) were labelled with fluorochrome-
conjugated mAb and analysed by four-colour flow cytometry. Data represents total numbers 
of group means ± SEM for (a) leukocytes (CD45+), (b) neutrophils (CD45+ Ly6G+ CD11b+) 
(c) macrophages (CD45+ Ly6G- CD11b+), and (d) T cells (CD45+ CD3+) in each cell 
suspension (n = 5 mice per group); symbols represent individual ears; ** P < 0.005, *** P < 
0.0001 compared to respective control ears. 
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